Indonesia develops its own Covid-19 vaccine


Indonesia, the country with the highest number of coronavirus cases at more than 115,000 and the highest coronavirus death toll in East Asia outside of China, is now pinning its hopes on vaccine developments, both autonomously in a domestic research institution and in cooperation with foreign biotech firms.

According to the Jakarta Post, a national consortium under the research and technology Ministry is working on developing its own vaccine under the helm of the Eijkman Institute for Molecular Biology in Jakarta. The vaccine will be named after Indonesia’s flag colors, merah putih, or red and white, and is planned for mass production in 2022.

While Indonesia is also seeking cooperation with foreign producers such as Sinovac Biotech of China and Genexine Inc. of South Korea, as well as the Bill Gates-backed Coalition for Epidemic Preparedness Innovations, the domestic vaccine development is meant as a longer-term, self-sufficient strategy.

All those developments are progressing at different paces and timelines, but they are expected to complement each other in order to cover Indonesia’s large population of more than 270 million people.

Vaccine soon ready for animal testing

Eijkman’s director Amin Soebandrio said his team was now entering the “critical process” that would determine the success of the merah putih vaccine in the future, namely the production of proteins by isolating genes and inserting them into cells. After two months, testing the proteins on animals could be started.

He said his team was making a vaccine specifically for the virus strain spread in Indonesia, which has similarities to the strain circulating around Asia.

The government has given Eijkman twelve months starting from April to develop vaccine prototypes that have been tested on animals, and then they would be handed over to state-owned pharmaceutical company PT Bio Farma for clinical trials. Bio Farma aims to mass-produce the vaccine by 2022 after getting approval from the Indonesian Food and Drug Monitoring Agency.

The merah putih vaccine, Soebandrio said, was expected to cover at least 50 per cent of Indonesia’s vaccine needs, given the country’s large population.



Support ASEAN news

Investvine has been a consistent voice in ASEAN news for more than a decade. From breaking news to exclusive interviews with key ASEAN leaders, we have brought you factual and engaging reports – the stories that matter, free of charge.

Like many news organisations, we are striving to survive in an age of reduced advertising and biased journalism. Our mission is to rise above today’s challenges and chart tomorrow’s world with clear, dependable reporting.

Support us now with a donation of your choosing. Your contribution will help us shine a light on important ASEAN stories, reach more people and lift the manifold voices of this dynamic, influential region.

$
Personal Info

Donation Total: $10.00

 

 

Indonesia, the country with the highest number of coronavirus cases at more than 115,000 and the highest coronavirus death toll in East Asia outside of China, is now pinning its hopes on vaccine developments, both autonomously in a domestic research institution and in cooperation with foreign biotech firms. According to the Jakarta Post, a national consortium under the research and technology Ministry is working on developing its own vaccine under the helm of the Eijkman Institute for Molecular Biology in Jakarta. The vaccine will be named after Indonesia's flag colors, merah putih, or red and white, and is planned for...


Indonesia, the country with the highest number of coronavirus cases at more than 115,000 and the highest coronavirus death toll in East Asia outside of China, is now pinning its hopes on vaccine developments, both autonomously in a domestic research institution and in cooperation with foreign biotech firms.

According to the Jakarta Post, a national consortium under the research and technology Ministry is working on developing its own vaccine under the helm of the Eijkman Institute for Molecular Biology in Jakarta. The vaccine will be named after Indonesia’s flag colors, merah putih, or red and white, and is planned for mass production in 2022.

While Indonesia is also seeking cooperation with foreign producers such as Sinovac Biotech of China and Genexine Inc. of South Korea, as well as the Bill Gates-backed Coalition for Epidemic Preparedness Innovations, the domestic vaccine development is meant as a longer-term, self-sufficient strategy.

All those developments are progressing at different paces and timelines, but they are expected to complement each other in order to cover Indonesia’s large population of more than 270 million people.

Vaccine soon ready for animal testing

Eijkman’s director Amin Soebandrio said his team was now entering the “critical process” that would determine the success of the merah putih vaccine in the future, namely the production of proteins by isolating genes and inserting them into cells. After two months, testing the proteins on animals could be started.

He said his team was making a vaccine specifically for the virus strain spread in Indonesia, which has similarities to the strain circulating around Asia.

The government has given Eijkman twelve months starting from April to develop vaccine prototypes that have been tested on animals, and then they would be handed over to state-owned pharmaceutical company PT Bio Farma for clinical trials. Bio Farma aims to mass-produce the vaccine by 2022 after getting approval from the Indonesian Food and Drug Monitoring Agency.

The merah putih vaccine, Soebandrio said, was expected to cover at least 50 per cent of Indonesia’s vaccine needs, given the country’s large population.



Support ASEAN news

Investvine has been a consistent voice in ASEAN news for more than a decade. From breaking news to exclusive interviews with key ASEAN leaders, we have brought you factual and engaging reports – the stories that matter, free of charge.

Like many news organisations, we are striving to survive in an age of reduced advertising and biased journalism. Our mission is to rise above today’s challenges and chart tomorrow’s world with clear, dependable reporting.

Support us now with a donation of your choosing. Your contribution will help us shine a light on important ASEAN stories, reach more people and lift the manifold voices of this dynamic, influential region.

$
Personal Info

Donation Total: $10.00

 

 

NO COMMENTS

Leave a Reply